Reviewer's report
Title:Allopurinol use in pregnancy in three women with inflammatory bowel
disease: safety and outcomes: a case series.
Version: 1Date:25 August 2013
Reviewer: John K Triantafillidis
Reviewer's report:
MINOR ESSENTIAL REVISIONS
Allopurinol and azathioprine have been categorized by the FDA as C and D
respectively. Therefore, even though the risk (at least for azathioprine) seems
minimal, combination use of these drugs in pregnant women with IBD must be
applied only after full explanation of the possible risks and benefits. This must be
repeatedly emphasized in the text.
We also suggest that authors should mention the results of a recent description
(Hoeltzenbein M, Stieler K, Panse M, Wacker E, Schaefer C. Allopurinol Use
during Pregnancy - Outcome of 31 Prospectively Ascertained Cases and a
Phenotype Possibly Indicative for Teratogenicity. PLoS One. 2013 Jun
19;8(6):e66637. Print 2013.) According to this, among 31 prospectively
ascertained pregnancies with allopurinol exposure there was one child with
severe malformations. The authors recommend caution with allopurinol treatment
in the first trimester, until further data are available.
Level of interest: An article of importance in its field
Quality of written English: Acceptable
Statistical review: No, the manuscript does not need to be seen by a
statistician.
Declaration of competing interests:
'I declare that I have no competing interests'
Reviewer's report
Title:Allopurinol use in pregnancy in three women with inflammatory bowel
disease: safety and outcomes: a case series.
Version: 1Date:25 August 2013
Reviewer: John K Triantafillidis
Reviewer's report:
MINOR ESSENTIAL REVISIONS
Allopurinol and azathioprine have been categorized by the FDA as C and D
respectively. Therefore, even though the risk (at least for azathioprine) seems
minimal, combination use of these drugs in pregnant women with IBD must be
applied only after full explanation of the possible risks and benefits. This must be
repeatedly emphasized in the text.
We also suggest that authors should mention the results of a recent description
(Hoeltzenbein M, Stieler K, Panse M, Wacker E, Schaefer C. Allopurinol Use
during Pregnancy - Outcome of 31 Prospectively Ascertained Cases and a
Phenotype Possibly Indicative for Teratogenicity. PLoS One. 2013 Jun
19;8(6):e66637. Print 2013.) According to this, among 31 prospectively
ascertained pregnancies with allopurinol exposure there was one child with
severe malformations. The authors recommend caution with allopurinol treatment
in the first trimester, until further data are available.
Level of interest: An article of importance in its field
Quality of written English: Acceptable
Statistical review: No, the manuscript does not need to be seen by a
statistician.
Declaration of competing interests:
'I declare that I have no competing interests'
Please review this paper.
user
Reviewer's report
Title:Allopurinol use in pregnancy in three women with inflammatory bowel
disease: safety and outcomes: a case series.
Version: 1Date:25 August 2013
Reviewer: John K Triantafillidis
Reviewer's report:
MINOR ESSENTIAL REVISIONS
Allopurinol and azathioprine have been categorized by the FDA as C and D
respectively. Therefore, even though the risk (at least for azathioprine) seems
minimal, combination use of these drugs in pregnant women with IBD must be
applied only after full explanation of the possible risks and benefits. This must be
repeatedly emphasized in the text.
We also suggest that authors should mention the results of a recent description
(Hoeltzenbein M, Stieler K, Panse M, Wacker E, Schaefer C. Allopurinol Use
during Pregnancy - Outcome of 31 Prospectively Ascertained Cases and a
Phenotype Possibly Indicative for Teratogenicity. PLoS One. 2013 Jun
19;8(6):e66637. Print 2013.) According to this, among 31 prospectively
ascertained pregnancies with allopurinol exposure there was one child with
severe malformations. The authors recommend caution with allopurinol treatment
in the first trimester, until further data are available.
Level of interest: An article of importance in its field
Quality of written English: Acceptable
Statistical review: No, the manuscript does not need to be seen by a
statistician.
Declaration of competing interests:
'I declare that I have no competing interests'
assistant